Effect of administration route on the renal safety of contrast agents: A meta-analysis of randomized controlled trials

Journal of Nephrology

Volumn 25, Issue 3, 2012, Pages 290-301

  Dong, Mei ^a   Jiao, Zhanquan ^b   Liu, Tong ^b   Guo, Fangming ^c   Li, Guangping ^b  

^a Yu Huang Top Hospital of Yantai   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^c YANTAISHAN HOSPITAL   (China)

Author keywords

Administration route; Contrast agents; Contrast induced acute kidney injury; Meta analysis; Randomized controlled trials

Indexed keywords

CONTRAST MEDIUM; FUROSEMIDE; IODIXANOL; IOHEXOL; IOMEPROL; IOPAMIDOL; IOPROMIDE; IOVERSOL; IOXAGLIC ACID; LOW OSMOLAR CONTRAST MEDIUM; MANNITOL; UNCLASSIFIED DRUG;

ADVERSE DRUG REACTION; ARTICLE; COCHRANE LIBRARY; CONFIDENCE INTERVAL; CONTRAST INDUCED ACUTE KIDNEY INJURY; DRUG SAFETY; EMBASE; HUMAN; INFORMATION RETRIEVAL; KIDNEY FUNCTION; MEDLINE; META ANALYSIS (TOPIC); NEPHROTOXICITY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION;

ACUTE KIDNEY INJURY; AGED; CONTRAST MEDIA; DRUG ADMINISTRATION ROUTES; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SAFETY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TRIIODOBENZOIC ACIDS;

EID: 84863330442     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000067     Document Type: Article

References (61)

1. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. Kidney Int Suppl. 2006;(100):S3-S7.
2. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259-2264.
3. Goldman SA, Johnson LL, Escala E, Cannon PJ, Weiss MB. Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure. Am J Med. 1980;68(1): 36-42.
4. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol. 2006;17(10):2871-2877.
5. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602-1613.
6. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol. 2006;48(4):692-699.
7. Heinrich MC, Häberle L, Müller V, Bautz W, Uder M. Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology. 2009;250(1):68-86.
8. Reed M, Meier P, Tamhane UU, Welch KB, Moscucci M, Gurm HS. The relative renal safety of iodixanol compared with lowosmolar contrast media: a meta-analysis of randomized controlled trials. JACC Cardiovasc Interv. 2009;2(7):645-654.
9. Pflueger A, Abramowitz D, Calvin AD. Role of oxidative stress in contrast-induced acute kidney injury in diabetes mellitus. Med Sci Monit. 2009;15(6):125-136.
10. Heyman SN, Rosen S, Khamaisi M, Idée JM, Rosenberger C. Reactive oxygen species and the pathogenesis of radiocontrast-induced nephropathy. Invest Radiol. 2010;45(4):188-195.
11. Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Available at: http://www.cochrane.org/ training/cochrane-handbook. Accessed December 25, 2011.
12. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF; VALOR Trial Investigators. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J. 2008;156(4):776-782.
13. Solomon RJ, Natarajan MK, Doucet S, et al; Investigators of the CARE Study. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation. 2007;115(25):3189-3196.
14. Feldkamp T, Baumgart D, Elsner M, et al. Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. Clin Nephrol. 2006;66(5):322-330.
15. Mehran R, Nikolsky E, Kirtane AJ, et al. Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus non-ionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. JACC Cardiovasc Interv. 2009;2(5):415-421.
16. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. J Am Coll Cardiol. 2006;48(5):924-930.
17. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ; Nephrotoxicity in High-Risk Patients Study of Iso-Osmolar and Low-Osmolar Non-Ionic Contrast Media Study Investigators. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med. 2003;348(6):491-499.
18. Chalmers N, Jackson RW. Comparison of iodixanol and iohexol in renal impairment. Br J Radiol. 1999;72(859):701-703.
19. Hardiek KJ, Katholi RE, Robbs RS, Katholi CE. Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. J Diabetes Complications. 2008;22(3):171-177.
20. Hill JA, Cohen MB, Kou WH, et al. Iodixanol, a new isosmotic nonionic contrast agent compared with iohexol in cardiac angiography. Am J Cardiol. 1994;74(1):57-63.
21. Kløw NE, Levorstad K, Berg KJ, et al. Iodixanol in cardioangiography in patients with coronary artery disease: tolerability, cardiac and renal effects. Acta Radiol. 1993;34(1):72-77.
22. Andersen PE, Bolstad B, Berg KJ, Justesen P, Thayssen P, Kloster YF. Iodixanol and ioxaglate in cardioangiography: a double-blind randomized phase III study. Clin Radiol. 1993;48(4):268-272.
23. Nie B, Cheng WJ, Li YF, et al. A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. Catheter Cardiovasc Interv. 2008;72(7):958-965.
24. Schmid I, Didier D, Pfammatter T, et al. Effects of non-ionic iodinated contrast media on patient heart rate and pressures during intra-cardiac or intra-arterial injection. Int J Cardiol. 2007;118(3):389-396.
25. Barrett BJ, Katzberg RW, Thomsen HS, et al. Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. Invest Radiol. 2006;41(11):815-821.
26. Carraro M, Malalan F, Antonione R, et al. Effects of a dimeric vs a monomeric nonionic contrast medium on renal function in patients with mild to moderate renal insufficiency: a doubleblind, randomized clinical trial. Eur Radiol. 1998;8(1):144-147.
27. Fischbach R, Landwehr P, Lackner K, et al. Iodixanol vs iopamidol in intravenous DSA of the abdominal aorta and lower extremity arteries: a comparative phase-III trial. Eur Radiol. 1996;6(1):9-13.
28. Kuhn MJ, Chen N, Sahani DV, et al. The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low-or isoosmolar contrast agent exposure. AJR Am J Roentgenol. 2008;191(1):151-157.
29. Nguyen SA, Suranyi P, Ravenel JG, et al. Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. Radiology. 2008;248(1):97-105.
30. Thomsen HS, Morcos SK, Erley CM, et al; Investigators in the Abdominal Computed Tomography: IOMERON 400 Versus VISIPAQUE 320 Enhancement (ACTIVE) Study. The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. Invest Radiol. 2008;43(3):170-178.
31. Siegle RL, Gavant ML. Comparison of iodixanol with iohexol in excretory urography. Acad Radiol. 1996;3(Suppl 3):524-527.
32. Tveit K, Bolz KD, Bolstad B, et al. Iodixanol in cardioangiography: a double-blind parallel comparison between iodixanol 320 mg I/ml and ioxaglate 320 mg I/ml. Acta Radiol. 1994;35(6):614-618.
33. Thorstensen O, Albrechtsson U, Calissendorff B, et al. Iodixanol in femoral arteriography: a randomized, double-blind, phase III, parallel study with iodixanol 270 mg I/ml and iohexol 300 mg I/ml. Acta Radiol. 1994;35(6):629-631.
34. Singh K, Sundgren R, Bolstad B, Björk L, Lie M. Iodixanol in abdominal digital subtraction angiography: a randomized, double-blind, parallel trial with iodixanol and iohexol. Acta Radiol. 1993;34(3):242-245.
35. Pugh ND, Sissons GR, Ruttley MS, Berg KJ, Nossen JO, Eide H. Iodixanol in femoral arteriography (phase III): a comparative double-blind parallel trial between iodixanol and iopromide. Clin Radiol. 1993;47(2):96-99.
36. Jakobsen JA, Berg KJ, Kjaersgaard P, et al. Angiography with nonionic X-ray contrast media in severe chronic renal failure: renal function and contrast retention. Nephron. 1996;73(4):549-556.
37. Verow P, Nossen JO, Sheppick A, Kjaersgaard P. A comparison of iodixanol with iopamidol in aorto-femoral angiography. Br J Radiol. 1995;68(813):973-978.
38. Lee FT Jr, Caroline DF, Thornbury JR, et al. A randomized comparison of iodixanol and iohexol in adult body computed tomography scanning. Acad Radiol. 1996;3(Suppl 3):500-506.
39. Hoste EA, De Waele JJ, Gevaert SA, Uchino S, Kellum JA. Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. Nephrol Dial Transplant. 2010;25(3):747-758.
40. Brown JR, Block CA, Malenka DJ, O'Connor GT, Schoolwerth AC, Thompson CA. Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. JACC Cardiovasc Interv. 2009;2(11):1116-1124.
41. Brar SS, Hiremath S, Dangas G, Mehran R, Brar SK, Leon MB. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and metaanalysis. Clin J Am Soc Nephrol. 2009;4(10):1584-1592.
42. Meier P, Ko DT, Tamura A, Tamhane U, Gurm HS. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med. 2009;7(1):23.
43. Kanbay M, Covic A, Coca SG, Turgut F, Akcay A, Parikh CR. Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol. 2009;41(3):617-627.
44. Joannidis MM, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr. 2008;120(23-24):742-748.
45. Ho KM, Morgan DJ. Use of isotonic sodium bicarbonate to prevent radiocontrast nephropathy in patients with mild preexisting renal impairment: a meta-analysis. Anaesth Intensive Care. 2008;36(5):646-653.
46. Hogan SE, L'Allier P, Chetcuti S, et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J. 2008;156(3):414-421.
47. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrastinduced nephropathy. Ann Intern Med. 2008;148(4):284-294.
48. Gawenda M, Möller A, Wassmer G, Brunkwall J. N-Acetylcystein in der Prophylaxe der Kontrastmittel-induzierten Nephropathie. Zentralbl Chir. 2007;132(3):227-231.
49. Liu R, Nair D, Ix J, Moore DH, Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med. 2005;20(2): 193-200.
50. Duong MH, MacKenzie TA, Malenka DJ. N-Acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv. 2005;64(4):471-479.
51. Misra D, Leibowitz K, Gowda RM, Shapiro M, Khan IA. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol. 2004;27(11):607-610.
52. Bagshaw SM, Ghali WA. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med. 2004;2(1):38.
53. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant. 2004;19(11):2747-2753.
54. Goldenberg I, Shechter M, Matetzky S, et al. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography: a randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212-218.
55. Alonso A, Lau J, Jaber BL, Weintraub A, Sarnak MJ. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis. 2004;43(1):1-9.
56. Isenbarger DW, Kent SM, O'Malley PG. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol. 2003;92(12):1454-1458.
57. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet. 2003;362(9384):598-603.
58. Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis. 2009;54(4):602-609.
59. Song K, Jiang S, Shi Y, Shen H, Shi X, Jing D. Renal replacement therapy for prevention of contrast-induced acute kidney injury: a meta-analysis of randomized controlled trials. Am J Nephrol. 2010;32(5):497-504.
60. Wassmann S, Wassmann K, Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension. 2004;44(4):381-386.
61. Cai H. Hydrogen peroxide regulation of endothelial function: origins, mechanisms, and consequences. Cardiovasc Res. 2005;68(1):26-36.